Expertos Invitados





DIAGNOSTICO DIFERENCIAL DE LOS PROLACTINOMAS

(especial para SIIC © Derechos reservados)
Distinguir los prolactinomas de los seudoprolactinomas es esencial debido que la terapia para cada uno de ellos es completamente diferente: médica para los primeros, quirúrgica en los últimos.
Autor:
Marco Losa
Columnista Experto de SIIC

Institución:
Università Vita-Salute

Artículos publicados por Marco Losa
Coautor
Paolo Ribotto* 
MD, Università Vita-Salute, Milán, Italia*
Recepción del artículo
2 de Noviembre, 2007 		Aprobación
23 de Enero, 2008
Primera edición
25 de Marzo, 2009 		Segunda edición, ampliada y corregida
7 de Junio, 2021

DIAGNOSTICO DIFERENCIAL DE LOS PROLACTINOMAS

Resumen
La hiperprolactinemia puede deberse tanto a adenomas hipofisarios que secretan prolactina (prolactinomas) como a tumores selares no funcionantes (denominados "seudoprolactinomas"). La relación entre el tamaño del tumor y el grado de prolactinemia habitualmente permite distinguir los prolactinomas de los seudoprolactinomas; este diagnóstico diferencial es esencial, dado que la terapia es completamente diferente (médica en el primer caso, quirúrgica en el último). La posible coexistencia de otras causas fisiológicas, patológicas o yatrogénicas de hiperprolactinemia, así como artefactos de laboratorio ("efecto gancho") y la presencia de variantes de prolactina desprovistas de actividad biológica (macroprolactinas) puede dar origen a errores. Los médicos deben conocer estos trastornos, dado que cuando no se reconocen se pueden realizar tratamientos inapropiados.

Palabras clave
neoplasia hipofisaria, prolactina, adenomas hipofisarios no funcionantes, cirugía de hipófisis


Artículo completo
(castellano)
Extensión:  +/-7.53 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Pitfalls in Distinguishing True Prolactinomas from "Pseudoprolactinomas"

Abstract
Hyperprolactinemia can be due to both prolactin-secreting pituitary adenomas (prolactinomas) and nonfunctioning sellar tumors (so called "pseudoprolactinomas"). The ratio between the size of the lesion and the degree of hyperprolactinemia usually permits to distinguish prolactinomas from pseudoprolactinomas; this differential diagnosis is essential, since therapy is entirely different (medical in the former case, surgical in the latter). The possible coexistence of other physiologic, pathologic or iatrogenic cause of hyperprolactinemia, as well as laboratory artifacts ("hook effect") and the presence of prolactin variants devoid of biological activity (macroprolactins) can give origin to pitfalls. Clinicians should be aware of these conditions, since inappropriate treatments can result if they are not recognized.

Key words
pituitary neoplasm, prolactin, nonfunctioning pituitary adenomas, pituitary surgery


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neurocirugía
Relacionadas: Atención Primaria, Bioquímica, Diagnóstico por Imágenes, Diagnóstico por Laboratorio, Endocrinología y Metabolismo, Farmacología, Medicina Interna



Comprar este artículo
Extensión: 7.53 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Marco Losa, Istituto Scientifico San Raffaele Dept. of Neurosurgery, 20132, Via Olgettina 60, Milán, Italia
Bibliografía del artículo

1. Schlechte J. Prolactinoma. N Engl J Med 349:2035-41, 2003.
2. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endondocrinol Metabol 68:412-8, 1989.
3. Abrahamson MJ, Snyder PJ. Causes of hyperprolactinemia. UpToDate 15.2 2007 www.uptodate.com.
4. Arafah MB, Neckl KE, Gold RS, Selman WR. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab 80:3507-12, 1995.
5. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22:1085-96, 2000.
6. Grubb MR, Chakeres D, Malarkey WB. Patients with primary hypothyroidism presenting as prolactinomas. Am J Med 83:765-9, 1987.
7. Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and patients with chronic renal failure. J Clin Endocrinol Metab 50:846-52, 1980.
8. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumors shrinkage. Endocr Rev 13:220-40, 1992.
9. Losa M, Mortini P, Barzaghi R et al. Endocrine inactive and gonadotroph adenomas: diagnosis and treatment. J Neuro-Oncol 54:167-77, 2001.
10. Snyder PJ. Clinical manifestation and diagnosis of hyperprolactinemia. UpToDate 15.2 2007 www.uptodate.com.
11. Smith TP, Kavanagh L, Healy ML, McKenna TJ. Technology insight: measuring prolactin in clinical practice. Nat Clin Pract Endocrinol Metab 3:279-89, 2007.
12. Haller BL. Two automated prolactin immunoassays evaluated with demonstration of a high-dose hook effect in one. Clin Chem 38:437-8, 1992.
13. Petakov MA. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 21;184-8, 1998.
14. St-Jean E. High prolactin levels may be missed by immunoradiometric assays in patients with macroprolactinomas. Clin Endocrinol (Oxf) 44:305-9, 1996.
15. Frieze TW. "Hook effect" in prolactinomas: case report and review of literature. Endocr Pract 8:296-303, 2002.
16. Smith CR, Norman MR. Prolactin and growth hormone: molecular heterogeneity and measurement in serum. Ann Clin Biochem 27:542-50, 1990.
17. Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG. Some forms of big big prolactin behave as a complex of monomeric prolactin and an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J Clin Endocrinol Metab 80:2342-6, 1995.
18. Hattori N. The frequency of macroprolactinemia in pregnant women and the heterogeneity of its aetiologies. J Clin Endocrinol Metab 81:586-90, 1996.
19. Sadideen H, Swaminathan R. Macroprolactin: what is it and what is its importance? Int J Clin Pract 60:457-61, 2006.
20. Glezer A, Carlos R, Soares J, et al. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab 91:1048-55, 2007.
21. Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassays and clearance studies of PRL immunoglobulin G complex. J Clin Endocrinol Metab 82:3107-10, 1997.
22. Olugoka AO, Kane J. Macroprolactinemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf) 51:119-26, 1999.
23. Bjoro T, Morkrid L, Wergeland R, et al. Frequency of hyperprolactinaemia due to large molecular weight (150-170 kD PRL). Scand J Clin Lab Invest 55:139-47, 1995.
24. Miyai K, Ichihara K, Kondo K, Mori S. Asymptomatic hyperprolactinaemia and prolactinoma in the general population: mass screening by paired assays of serum prolactin. Clin Endocrinol (Oxf) 25:549-54, 1986.
25. Cattaneo FA, Fahie-Wilson MN. Concomitant occurrence of macroprolactin, exercise-induced amenorrhea, and a pituitary lesion: a diagnostic pitfall. Case report. J Neurosurg 95:334-47, 2001.
26. Vallette-Kasic S, Morange-Ramos I, Selim A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 87:581-88, 2002.
27. Hauache OM, Rocha AJ, Maia Jr ACM, Maciel RMB, Vieira JGH. Screening for macroprolactinemia and pituitary imaging studies. Clin Endocrinol (Oxf) 57:327-31, 2002.
28. Molitch ME, Russell EJ. The pituitary "incidentaloma". Ann Intern Med 112:925-31, 1990.
29. Snyder PJ. Pituitary incidentaloma. UpToDate 15.2 2007 www.uptodate.com.
30. Losa M, mortini P, Giovanelli M. A non-functioning pituitary adenoma initially mimicking a microprolactinoma: the case for long-term follow-up of patients with mild hyperprolactinemia? J Endocrinol Invest 27:367-70, 2004.
31. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Endocrinol Clin Metab 87:3180-6, 2002.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008